Under 10% of people who could benefit from obesity jabs including Wegovy can access them, caution the WHO as it issues its first advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for increased and just access to these injectable treatments.
Per estimates, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"The latest guidance acknowledges that excess weight is a chronic disease that can be managed with thorough and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are key obstacles to widespread availability to the treatments that can assist patients in reducing considerable body mass, says the body.
GLP-1 Therapy Supply Crisis
Even in the present most favorable case, the supply of these medications might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the WHO.
The guideline calls on countries and companies to widen availability, by strategies such as patent sharing.
A patent on semaglutide – the core ingredient of a leading brand – is due to expire in multiple nations in 2026.
The Way Weight-Loss Drugs Function
These medications imitate a body's own hormone to slow digestion, suppress the appetite and boost the sense of being full so individuals eat less.
People typically see weight reduction after several weeks of commencing the once-weekly jabs.
Studies points to patients may regain a significant portion within a year of stopping the drug, as their usual hunger come back.
Being overweight or obese elevates your risk for experiencing medical conditions, such as diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity impacts people in all nations and was associated with 3.7 million fatalities worldwide in 2024, per the WHO.
